Blinatumomab
NK-Cell Leukemia
St. Jude Children's Research Hospitalmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the NK-Cell Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide The Affiliated Hospital of Xuzhou Medical University | Phase 2 | B |
Evomela St. Jude Children's Research Hospital | Phase 2 | CCC |
Thiotepa St. Jude Children's Research Hospital | Phase 2 | CCC |
Anti-Thymoglobulin, Rabbit St. Jude Children's Research Hospital | Phase 2 | CCC |
Mesna St. Jude Children's Research Hospital | Phase 2 | CCC |
View all 21 →
Same molecule, other indications
Blinatumomab is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →